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tocellular carcinoma (HCC) rates and health care costs of treated and untreated 
patients were compared using propensity score matching. Baseline demographic 
and clinical factors were controlled in the models. Subgroup analysis was con-
ducted for patient groups with and without a cirrhosis diagnosis. Results: A total 
12,990 patients, of whom 2,467 were diagnosed with cirrhosis, were included in the 
study. 12.2% of the overall population was treated for HCV. Treated patients were 
younger, less likely to reside in Central or Eastern Anatolia and less likely to have 
comorbidities. After adjusting for baseline demographic and clinical factors, mor-
tality rates (2.27% vs. 5.31%, p< 0.001) and HCC rates (0.69% vs. 1.96%, p< 0.001) were 
significantly lower for treated HCV patients. The differences were more significant 
among cirrhosis patients. Total risk-adjusted annual costs were significantly higher 
for treated patients (€ 6,172 vs. € 1,680, p< 0.001), mainly due to higher pharmaceutical 
costs (€ 4,918 vs. € 583, p< 0.001). ConClusions: HCV treatment, although costly, 
significantly reduces mortality and HCC rates in Turkey.
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objeCtives: Health care workers (HCW) are at particular risk of acquiring pertussis 
and transmitting the infection to high-risk susceptible patients and colleagues. In 
this paper, the Return On Investment (ROI) of preventively vaccinating HCW against 
pertussis to prevent nosocomial pertussis outbreaks is estimated using a hospi-
tal ward perspective, presuming an outbreak occurs once in 10 years. Methods: 
Data on the pertussis outbreak on the neonatology ward in 2004 in the Academic 
Medical Center Amsterdam (The Netherlands) was used to calculate control costs 
and other outbreak related costs. The study population was: neonatology ward 
staff members (n= 133), parents (n= 40), neonates (n= 20), and newborns transferred 
to other hospitals (n= 23). ROI is presented as the amount of Euros saved in avert-
ing outbreaks by investing one Euro in preventively vaccinating HCW. Sensitivity 
analysis was performed to study the robustness of the ROI. Results are presented at 
2012 price level. Results: Total nosocomial pertussis outbreak costs were € 48,682. 
Direct control costs (i.e. Antibiotic therapy, laboratory investigation and outbreak 
management control) were € 11,464. Other outbreak related costs (i.e. sick leave of 
HCW; restrictions on the neonatology ward, savings due to reduced working force) 
accounted for € 37,218. Vaccination costs would be € 12,208. The ROI of preventively 
vaccinating HCW against pertussis was 1: 4, meaning 4 Euros could be saved by every 
Euro invested in vaccinating HCW to avert outbreaks. ROI was sensitive to a lower 
vaccine price, considering direct control costs only, average length of stay neonates 
on the neonatology ward, length of patient uptake restrictions, assuming no reduced 
work force due to ward closer and presuming more than one outbreak to occur in 10 
years’ time. ConClusions: From a hospital ward perspective, preventive vaccina-
tion of HCW against pertussis to prevent nosocomial pertussis outbreaks results in 
a positive ROI, presuming an outbreak occurs once in 10 years.
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objeCtives: Methicillin-resistant Staphylococcus aureus (MRSA) infections cause 
heavy financial burden on health care systems worldwide. Hospital admission 
screening has been proven as an effective method to prevent nosocomial MRSA 
transmission. However, previous cost studies mostly refer to screening regimes 
for a limited area of hospitals (e. g. ICU) a limited period of intervention (< 1 year) 
or rely on culture tests only. The aim of this study was to determine the long-term 
costs and benefits of a targeted hospital wide PCR-based admission screening for 
MRSA. Methods: We performed a six-year (2008-2013) retrospective analysis of 
the step-wise implementation of a hospital-wide PCR-based admission screening 
of defined risk patients for MRSA in a 926-bed tertiary hospital. Screening costs 
includes PCR-screening (screening rate 10.7-14.7%) and cultural test confirmation in 
case of a positive test result as well as hygienic measures for pre-emptive isolation 
of all screened patients. The benefit is calculated based on prevented nosocomial 
MRSA infections (reference year 2007), assuming that 8,673 Euros will be saved per 
case. Results: During the study period, prevented nosocomial MRSA-infections 
resulted in total cost savings of at least 1,329,714 Euros. This is opposed by costs for 
targeted PCR-screening of 670,234 Euros and 441,448 Euros for pre-emptive isolation 
measures. The save/cost-ratio was calculated with 1.196, the save-cost-difference 
with 36,339 Euros per year. ConClusions: Our study shows the advantage of a 
PCR-based admission screening by a positive cost-saving-difference. Nevertheless, 
this advantage depends on cost drivers included in the analysis and the definition 
of risk factors which determine the proportion of patients to be screened. For a true 
image, the opportunity costs for reimbursement losses due to blocked beds during 
isolation as well as additional savings for prevented nosocomial MRSA-colonizations 
have to be taken into consideration.
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per 1 patient: 1. Flu patients at PCP, average number of visits/patient in 2009-2010 were 
7753635 sick persons, 2010-2011– 7502008 sick persons. Total cost of the disease was 
80,39 UAH per 1 patient (1 Euro= 10 UAH on 01.06.2011). 2. Flu patients in out-patient 
clinic during 2009/10 were registered 1962839 request for medical assistance about 
influenza and ARI. In the season, 2010/11 - registered 1785102 who needed medical 
care for influenza and ARI, total cost was 202,07 UAH. 3. Flu patients in hospital dur-
ing 2009-2010 were hospitalized 47108 persons. Total cost of the disease was 728,85 
UAH. 4. Flu patients in intensive care unit – the total cost of the disease was 2543,08 
UAH. ConClusions: Established the high costs for the hospitalization were 2543,08 
UAH per 1 patient comparіng with 80,39 UAH at PCP. Govermental program to prevent 
influenza by vaccination can to reduce the cost of flu treating.
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objeCtives: 3-11% of patients diagnosed with chronic hepatitis C virus (HCV) 
infection will develop liver cirrhosis within 20-30 years, with an associated risk 
of liver failure and hepatocellular carcinoma (HCC). Mortality, HCC rates and costs 
of HCV patients were compared among cirrhosis and non-cirrhosis patients in 
Turkey. Methods: Using the Turkish National Health Insurance Database (2009-
2011), HCV patients were identified using International Classification of Disease, 
10th Revision, Clinical Modification codes. Propensity score matching (PSM) was 
applied to compare cirrhosis and non-cirrhosis cohorts. Baseline demographic and 
clinical factors were controlled in the models. Results: A total of 12,990 patients, 
including 2,467 diagnosed with cirrhosis, were included in the study. 12.2% of the 
overall population was treated. Cirrhosis patients were older (61.56 vs. 51.10 years, 
p< 0.001), more likely to reside in the Black Sea region (26.96% vs. 23.77%, p< 0.001) 
and had Elixhauser comorbidity index scores ≥ 2 (89.30% vs. 66.06%, p< 0.001). In par-
ticular, these patients were more likely to be diagnosed with comorbidities such as 
biliary disease, hepatitis B, congestive heart disease, respiratory disease, hyperten-
sion and diabetes. After all baseline differences were controlled, patients diagnosed 
with cirrhosis showed higher mortality (23.87% vs. 5.14%, p< 0.001) and HCC rates 
(8.10% vs. 1.05%, p< 0.001). Disease-related costs were significantly higher (€ 3,254 
vs. € 1,996; p< 0.001). ConClusions: Cirrhosis mortality, HCC rates and costs of 
cirrhosis among HCV patients are significantly higher in Turkey.
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objeCtives: Although prevention accounts for a minor part of the health care 
spending (< 3%) in Europe, preventative programs and particularly vaccinations 
are most vulnerable to budget cuts and restrictions as their benefits may not be 
immediately identifiable. This pan-European project aims at evaluating the lifelong 
costs per individual vaccinated in full compliance with the national recommenda-
tions. French results are presented below. Methods: A calculation Excel model 
was developed and fed with the most recent French specific data: 2014 vaccination 
calendar from High Council of Public Health, life expectancy at birth from WHO, 
list prices from National health insurance database (NHI: AMELI). Reimbursement 
rates were applied to total costs to reflect NHI perspective. A 100% compliance 
rate was assumed. When several vaccines were available for a similar preventative 
indication, the list price of the product with the highest 2013 market share was 
considered. Lifelong vaccine costs were calculated for 4 categories of individuals: 
man/woman, without/with underlying conditions. For individuals with underlying 
conditions, the following specific recommendations were considered: Tuberculosis, 
Hepatitis B, Influenza, Hepatitis A, Pertussis, Pneumococcal diseases, Varicella. 
Three recommended vaccinations (Zoster, Rotavirus, Meningococcal B diseases) 
without official prices were not included. Results: In 2014, total lifelong vaccines 
costs ranged from € 524 (men without underlying conditions) to € 1379 (women 
with underlying conditions), covering 12 to 16 diseases respectively. Differences 
in costs are linked to gender specificities (life expectancy, Human Papillomavirus 
vaccination), or to recommendations specific to underlying conditions. Since only 
reimbursed vaccines are considered, most of vaccines costs are funded by the NHI 
(72% to 82%). ConClusions: These total costs of vaccines throughout life should 
be considered as maximal since in practice few people fully comply with all recom-
mendations of the National vaccination calendar. Policy makers shall appreciate 
that prevention through vaccination involves low levels of investment relative to 
its substantial benefits.
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objeCtives: To compare health care outcomes between hepatitis c virus (HCV) 
patients who were prescribed pegylated interferon-alpha with or without ribavirin 
to those who were not prescribed these medications. Methods: Using the Turkish 
National Heath Insurance Database (2009-2011), HCV patients were identified using 
International Classification of Disease, 10th Revision, Clinical Modification codes. 
The first prescription date was designated as the index date. Mortality and hepa-
